-+ 0.00%
-+ 0.00%
-+ 0.00%

Northwest Bio appoints Annalisa Jenkins as strategic adviser

PUBT·04/30/2026 16:31:23
Listen to the news
Northwest Bio appoints Annalisa Jenkins as strategic adviser
  • Northwest Biotherapeutics appointed Annalisa Jenkins as strategic adviser to help expand its dendritic cell cancer vaccine platform.
  • Jenkins previously served as president and CEO of Dimension Therapeutics, which she took public on Nasdaq before its sale to Ultragenyx.
  • Her earlier roles included head of global R&D at Merck Serono, senior vice president and head of global medical affairs at Bristol-Myers Squibb.
  • Company is advancing DCVax-L for newly diagnosed and recurrent glioblastoma.
  • NWBio submitted a marketing authorization application to UK MHRA for DCVax-L.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604301230PR_NEWS_USPR_____SF48278) on April 30, 2026, and is solely responsible for the information contained therein.